摘要
[目的]比较Aidi-MVP方案与MVP方案对初治Ⅲ b～Ⅳ期非小细胞肺癌(NSCLC)病人的疗效、毒性及生活质量的改善情况。[方法]A组(34例)接受Aidi-MVP方案治疗 ;B组(36例)接受MVP方案治疗。两组均以4周为1个周期 ,重复3个周期。[结果]A、B两组(CR +PR)分别为26.5%及22.2 % ,P>0.05 ;中位生存期A组32周 ,B组27周(P<0.01) ;白细胞减少及恶心呕吐反应B组均较A组明显(P<0.01) ;两组均未发现其他严重的毒性反应。临床受益疗效A组高于B组(P<0.05)。[结论]艾迪配合MVP方案与单纯MVP方案治疗晚期NSCLC的客观疗效无明显差异性 ,但前者毒副反应小 ,中位生存期长 。
To compare the effect,toxicity and quality of life(QOL)between Aidi-MVP regimen and MVP regimen alone in primary patients with advanced non small cell lung cancer(NSCLC,stage Ⅲb～Ⅳ). Group A(34 cases)were treated with Aidi-MVP regimen and group B(36 cases),with MVP regimen.Both regimens were repeated every 4 weeks for three cycles. The objective response rate(CR+PR)was 26.5% in group A compared to 22.2% in group B(P>0.05).The median survival time was 32 weeks in group A compared to 27 weeks in group B(P<0.01).Leukopenia,nausea and vomiting in group B were more serious than those in group A(P<0.01).No other serious side effect occurred in either group.Clinical benefit response in group A was higher than that in group B(P<0.05).[Conclusion]The present study indicates that the patients with advanced NSCLC treated with Aidi-MVP regimen had lower toxicity,longer median survival time and better QOL than those treated with MVP regimen alone however there is no significant statistical difference in the objective response rate between the two groups.
出处
《肿瘤学杂志》
CAS
2002年第4期209-210,共2页
Journal of Chinese Oncology
关键词
艾迪
丝裂霉素
长春酰胺
顺铂
非小细胞肺癌
治疗
Aidi injection
mitomycin
vindesine
cisplatin
non_small cell lung cancer(NSCLC)
efficacy
